drugset / Trial / NCT04612465

Clinical Study to Evaluate Efficacy and Safety of ASC and Fibringlue or Fibringlue in Patients With Crohn's Fistula

NCT04612465

Phase 3 Active not recruiting 46 enrolled Anterogen Co., Ltd.
RandomizedParallel-groupOpen-labelPrevention

Summary

This is a phase III study to evaluate the efficacy and safety of ASC(Autologous Adipose-derived Stem Cells) and Fibringlue or Fibringlue in Patients With Crohn's Fistula.

Timeline

Start
2020-01-09
Primary completion
2025-04-08
Completion
2025-09-23

Drugs

EvaluationDrugModalityDoseRoute
Subject (Autologous Adipose-derived Mesenchymal Stem Cells) Cell therapy 1e+07 cells
Comparator Fibrinogen Concentrate Human Protein / enzyme biologic

Indications